Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.
CG
Immediate radical cystectomy
Immunotherapy
Non-muscle-invasive bladder cancer
T1
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
26
08
2021
accepted:
31
01
2022
pubmed:
27
2
2022
medline:
12
5
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
To compare cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and Bacillus Calmette-Guérin (BCG) immunotherapy for T1 squamous bladder cancer (BCa). We retrospectively analysed 188 T1 high-grade squamous BCa patients treated between 1998 and 2019 at fifteen tertiary referral centres. Median follow-up time was 36 months (interquartile range: 19-76). The cumulative incidence and Kaplan-Meier curves were applied for CSM and OM, respectively, and compared with the Pepe-Mori and log-rank tests. Multivariable Cox models, adjusted for pathological findings at initial transurethral resection of bladder (TURB) specimen, were adopted to predict tumour recurrence and tumour progression after BCG immunotherapy. Immediate RC and conservative management were performed in 20% and 80% of patients, respectively. 5-year CSM and OM did not significantly differ between the two therapeutic strategies (Pepe-Mori test p = 0.052 and log-rank test p = 0.2, respectively). At multivariable Cox analyses, pure squamous cell carcinoma (SqCC) was an independent predictor of tumour progression (p = 0.04), while concomitant lympho-vascular invasion (LVI) was an independent predictor of both tumour recurrence and progression (p = 0.04) after BCG. Patients with neither pure SqCC nor LVI showed a significant benefit in 3-year recurrence-free survival and progression-free survival compared to individuals with pure SqCC or LVI (60% vs. 44%, p = 0.04 and 80% vs. 68%, p = 0.004, respectively). BCG could represent an effective treatment for T1 squamous BCa patients with neither pure SqCC nor LVI, while immediate RC should be preferred among T1 squamous BCa patients with pure SqCC or LVI at initial TURB specimen.
Identifiants
pubmed: 35218372
doi: 10.1007/s00345-022-03958-9
pii: 10.1007/s00345-022-03958-9
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1167-1174Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Gontero P, Mostafid AH, Palou J et al (2019) European Association of Urology Guidelines on Non- muscle-invasive bladder cancer (TaT1 and carcinoma in situ)2019 update. Eur Urol 76(5):639–657. https://doi.org/10.1016/j.eururo.2019.08.016
doi: 10.1016/j.eururo.2019.08.016
pubmed: 31443960
Balakrishnan AS, Washington SL, Meng MV, Porten SP (2019) Determinants of guideline-based treatment in patients with cT1 bladder cancer. Clin Genitourin Cancer 17:e461–e471. https://doi.org/10.1016/j.clgc.2019.01.007
doi: 10.1016/j.clgc.2019.01.007
pubmed: 30799130
Patriarca C, Hurle R, Moschini M et al (2016) Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagn Pathol. https://doi.org/10.1186/s13000-016-0466-6
doi: 10.1186/s13000-016-0466-6
pubmed: 26791567
pmcid: 4721190
Colombo R, Hurle R, Moschini M et al (2018) Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer. Eur Urol Focus 4:87–93. https://doi.org/10.1016/j.euf.2016.06.004
doi: 10.1016/j.euf.2016.06.004
pubmed: 28753746
Horwich A, Babjuk M, Bellmunt J et al (2019) EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Ann Oncol 30:1697–1727. https://doi.org/10.1093/annonc/mdz296
doi: 10.1093/annonc/mdz296
pubmed: 31740927
Witjes JA, Babjuk M, Bellmunt J et al (2020) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer—An International Collaborative Multistakeholder Effort†. Eur Urol 77:223–250. https://doi.org/10.1016/j.eururo.2019.09.035
doi: 10.1016/j.eururo.2019.09.035
pubmed: 31753752
Babjuk M, Burger M, Compérat EM et al (2019) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—2019 Update. Eur Urol 76:639–657. https://doi.org/10.1016/j.eururo.2019.08.016
doi: 10.1016/j.eururo.2019.08.016
pubmed: 31443960
Naspro R, Finati M, Roscigno M et al (2020) The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre. World J Urol 39:1121–1135. https://doi.org/10.1007/s00345-020-03364-z
doi: 10.1007/s00345-020-03364-z
Rodler S, Buchner A, Ledderose ST et al (2020) Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy? World J Urol. https://doi.org/10.1007/s00345-020-03482-8
doi: 10.1007/s00345-020-03482-8
pubmed: 33084922
Lobo N, Shariat SF, Guo CC et al (2020) What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus 6:653–663. https://doi.org/10.1016/j.euf.2019.09.003
doi: 10.1016/j.euf.2019.09.003
pubmed: 31530497
Deuker M, Stolzenbach LF, Rosiello G et al (2020) Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2020.05.006
doi: 10.1016/j.ejso.2020.05.006
pubmed: 32457017
Porten SP, Willis D, Kamat AM (2014) Variant histology : role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol 24:517–523. https://doi.org/10.1097/MOU.0000000000000089
doi: 10.1097/MOU.0000000000000089
pubmed: 24921905
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
doi: 10.1097/00000421-198212000-00014
Owens WD, Felts JA, Spitznagel EL (1978) ASA physical status classifications: a study of consistency of ratings. Anesthesiology 49:239–243. https://doi.org/10.1097/00000542-197810000-00003
doi: 10.1097/00000542-197810000-00003
pubmed: 697077
Barbosa ALA, Vermeulen SHHM, Aben KK et al (2018) Smoking intensity and bladder cancer aggressiveness at diagnosis. PLoS ONE 13:e0194039. https://doi.org/10.1371/journal.pone.0194039
doi: 10.1371/journal.pone.0194039
pubmed: 29570711
pmcid: 5865728
Paner GP, Stadler WM, Hansel DE et al (2018) Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol 73:560–569. https://doi.org/10.1016/j.eururo.2017.12.018
doi: 10.1016/j.eururo.2017.12.018
pubmed: 29325693
Witjes JA, Bruins HM, Cathomas R et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79:82–104. https://doi.org/10.1016/j.eururo.2020.03.055
doi: 10.1016/j.eururo.2020.03.055
pubmed: 32360052
Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol 70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029
doi: 10.1016/j.eururo.2016.02.029
pubmed: 26935559
Mathieu R, Lucca I, Rouprêt M et al (2016) The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol 13:471–479. https://doi.org/10.1038/nrurol.2016.126
doi: 10.1038/nrurol.2016.126
pubmed: 27431340
Novara G, Svatek RS, Karakiewicz PI et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183:2165–2170. https://doi.org/10.1016/j.juro.2010.02.021
doi: 10.1016/j.juro.2010.02.021
pubmed: 20399473
Ehdaie B, Maschino A, Shariat SF et al (2012) Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J Urol 187:74–79. https://doi.org/10.1016/j.juro.2011.09.056.Comparative
doi: 10.1016/j.juro.2011.09.056.Comparative
pubmed: 22088332
Soria F, D’Andrea D, Abufaraj M et al (2020) Stratification of intermediate-risk non–muscle-invasive bladder cancer patients: implications for adjuvant therapies. Eur Urol Focus. https://doi.org/10.1016/j.euf.2020.05.004
doi: 10.1016/j.euf.2020.05.004
pubmed: 32532704
Scosyrev E, Yao J, Messing E (2009) Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 73:822–827. https://doi.org/10.1016/j.urology.2008.11.042
doi: 10.1016/j.urology.2008.11.042
pubmed: 19193403
Necchi A, Raggi D, Gallina A et al (2020) Updated Results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol 77:439–446. https://doi.org/10.1016/j.eururo.2019.10.026
doi: 10.1016/j.eururo.2019.10.026
pubmed: 31708296
Rosiello G, Pecoraro A, Palumbo C et al (2021) Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. World J Urol 39:813–822. https://doi.org/10.1007/s00345-020-03247-3
doi: 10.1007/s00345-020-03247-3
pubmed: 32424515
Suh J, Moon KC, Jung JH et al (2019) BCG instillation versus radical cystectomy for high-risk NMIBC with squamous / glandular histologic variants. Sci Rep 9:15268. https://doi.org/10.1038/s41598-019-51889-0
doi: 10.1038/s41598-019-51889-0
pubmed: 31649294
pmcid: 6813340
Gofrit ON, Yutkin V, Shapiro A et al (2016) The response of Variant histology Bladder cancer to intravesical immunotherapy compared to conventional cancer. Front Oncol 6:43. https://doi.org/10.3389/fonc.2016.00043
doi: 10.3389/fonc.2016.00043
pubmed: 27014622
pmcid: 4791377
Yorozuya W, Nishiyama N, Shindo T et al (2018) Bacillus Camlette-Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients : retrospective multicenter study. Jpn J Clin Oncol 48:661–666. https://doi.org/10.1093/jjco/hyy066
doi: 10.1093/jjco/hyy066
pubmed: 29733363
Shapur NK, Pode D, Shapiro A et al (2011) Is radical cystectomy mandatory in every patient with variant histology of bladder cancer? Rare Tumors 3:e22. https://doi.org/10.4081/rt.2011.e22
doi: 10.4081/rt.2011.e22
pubmed: 21769321
pmcid: 3132126